SF-36 domain scores at baseline and week 16 with apremilast 20 mg BID. Spydergram of SF-36 domain scores in patients receiving apremilast 20 mg BID versus US age-/gender-matched norms (lavender) and baseline (dark blue). Gridlines represent changes of 10 points each (10 points = 2× MCID). An increase in score indicates improvement. Treatment-associated improvements (light blue) are statistically significant in five and ≥MCID in six of eight domains. MCID, minimal clinically important difference; SF-36, 36-item Short-Form Health Survey. *≥MCID.